FindTrial
Sign In

FINE-START; A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in participants with chronic kidney disease not using renin-angiotensin-system inhibitors

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523075-32-00
Acronym
22817
Enrollment
55
Registered
2025-12-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Brief summary

Change in UACR from baseline (ratio to baseline) over 6 months

Detailed description

Number of participants with TEAEs, TESAEs, Number of participants with Hyperkalemia (AESI)

Interventions

DRUGPlacebo for BAY 94-8862
DRUGBAY 94-8862
DRUGFinerenone

Sponsors

Universitair Medisch Centrum Groningen
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in UACR from baseline (ratio to baseline) over 6 months—

Secondary

MeasureTime frame
Number of participants with TEAEs, TESAEs, Number of participants with Hyperkalemia (AESI)—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026